Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.79
-0.0500-0.64%
Post-market: 7.78-0.0103-0.13%19:59 EDT
Volume:7.62M
Turnover:59.32M
Market Cap:8.26B
PE:-7.88
High:7.95
Open:7.85
Low:7.60
Close:7.84
52wk High:12.43
52wk Low:1.95
Shares:1.06B
Float Shares:407.00M
Volume Ratio:0.99
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9887
EPS(LYR):-0.3820
ROE:78.05%
ROA:-30.54%
PB:-7.89
PE(LYR):-20.39

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Legence, Valero Energy, Stereotaxis

Reuters
·
Apr 06

BRIEF-Immunitybio Addresses FDA Correspondence And Reaffirms Commitment To Advertising Compliance

Reuters
·
Apr 06

Immunitybio Inc - Initiates Review and Implements Enhanced Advertising Compliance Measures

THOMSON REUTERS
·
Apr 06

Immunitybio Inc - Removes Identified Podcast and Requests Removal From Third-Party Platforms

THOMSON REUTERS
·
Apr 06

Immunitybio Inc - Submits Response to FDA Opdp Regarding Promotional Issues Raised on March 13, 2026

THOMSON REUTERS
·
Apr 06

Immunitybio Inc - Implements Corrective Actions Including Executive Training and External Regulatory Counsel

THOMSON REUTERS
·
Apr 06

Immunitybio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

THOMSON REUTERS
·
Apr 06

ImmunityBio says FDA-cited TV ad never aired, pulls podcast after OPDP letter

Reuters
·
Apr 06

BUZZ-U.S. STOCKS ON THE MOVE -Shake Shack, Perpetua, Caribou Biosciences

Reuters
·
Apr 01

ImmunityBio Secures $100 Million in Financing

MT Newswires Live
·
Mar 31

BUZZ-ImmunityBio rises as biotech secures $100 mln to fund global expansion

Reuters
·
Mar 31

BRIEF-Immunitybio Strengthens Balance Sheet With $100 Million Of Financing Transactions Including $75 Million Of Non-Dilutive Financing To Support Global Expansion And Advancement Of Broader Immunotherapy Pipeline

Reuters
·
Mar 31

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky

TIPRANKS
·
Mar 31

ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva

TIPRANKS
·
Mar 31

A Look At ImmunityBio (IBRX) Valuation After FDA Warning Letter On Anktiva Promotions

Simply Wall St.
·
Mar 27

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

BUZZ-ImmunityBio says bladder cancer therapy on track for filing, shares rise

Reuters
·
Mar 26

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Benzinga
·
Mar 26

ImmunityBio announces IDMC says QUILT-2.005 adequately powered

TIPRANKS
·
Mar 26

ImmunityBio confirms QUILT-2.005 trial remains adequately powered at N=366; supplemental BLA submission stays on track for 2026

Reuters
·
Mar 26